ClinicalTrials.gg
Not yet recruitingNCT07480317PD TISUpdated Mar 24, 2026

TIS for Brain Network Modulation and Clinical Efficacy in Parkinson's Disease

An interventional study of Temporal Interference Stimulation (130 Hz) and Temporal Interference Stimulation (40 Hz) in PARKINSON DISEASE (Disorder), sponsored by Jiangsu Province Nanjing Brain Hospital. Not yet recruiting at 1 site in China. Open to participants aged 45 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-24.

Sponsored by Jiangsu Province Nanjing Brain Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
45 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 279 studies in Parkinson Disease with a site in China — 128 open to participants now, 135 under way, 3 of them phase 3. Parkinson Disease · China.

Planned enrollment
68th of 211
75 · median 47
Started
2026
with 40 others
No phase
115 of 279
57 open now
Primary completion
2026-08
later than 53 of 134 live
Registered
243rd of 279
by date

Among the 279 studies in Parkinson Disease with a site in China, this one is the 68th largest by planned enrollment of the 211 interventional ones that give a count, is one of 41 that started in 2026, is one of 115 with no phase, reaches primary completion later than 53 of the 134 other live ones, and was the 243rd registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

128 of the 279 studies in Parkinson Disease with a site in China are open now. Recruiting first, the newest first:

123 more — sign in →

All 128 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 45 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 279 studies in Parkinson Disease with a site in China, or all of them as a file.
02

Study summary

Parkinson's disease (PD) is a neurodegenerative disorder characterized by motor dysfunction. While deep brain stimulation (DBS) is effective, its invasive nature limits its application in early-stage patients. Temporal interference stimulation (TIS) is a novel non-invasive technique that can target deep brain structures like the globus pallidus internus (GPi) by using high-frequency electric fields.

This study aims to evaluate the clinical value and underlying mechanisms of TIS in PD patients. The research is divided into two phases: Phase A investigates the immediate regulatory effects of 130 Hz and 40 Hz TIS on brain networks using concurrent fMRI-TIS. Phase B is a randomized, double-blind, sham-controlled trial to assess the long-term efficacy and safety of a 2-week TIS intervention on both motor and non-motor symptoms. The results will help clarify how TIS modulates deep brain networks and its potential as a non-invasive therapy for PD.

Read the detailed description

This study employs a two-phase design to systematically investigate the effects of Temporal Interference Stimulation (TIS) on Parkinson's Disease (PD).

Phase A: Acute fMRI Mechanism Study (n=15) In this crossover study, participants will undergo concurrent fMRI-TIS sessions. Two frequency envelopes will be tested: 130 Hz (to mimic DBS inhibitory effects) and 40 Hz (for gamma entrainment). The fMRI protocol follows an 8-20-8 minute design: 8 minutes of baseline, 20 minutes of concurrent stimulation, and 8 minutes of post-stimulation scan . Individualized electric field modeling based on high-resolution 3D-T1 MRI will be used to target the right GPi. Acute motor changes will be assessed using the MDS-UPDRS-III scale.

Phase B: Long-term Efficacy RCT (n=60) Participants will be randomly assigned to one of three parallel groups: 130 Hz TIS, 40 Hz TIS, or Sham stimulation. The intervention consists of 30-minute daily sessions for 2 weeks (10 sessions total).

Active Groups: TIS targeting the right GPi with individualized electrode configurations.

Sham Group: 20-second ramp-up and ramp-down to mimic skin sensation without continuous stimulation.

Clinical assessments including motor function (MDS-UPDRS), cognition (MoCA), mood (HAMD/HAMA), and sleep (PDSS-2) will be conducted at baseline, after the 2-week intervention, and at a 1-month follow-up . Long-term neuroplasticity will also be evaluated using multi-modal MRI post-intervention.

03

Conditions studied

  • PARKINSON DISEASE (Disorder)

Browse trials for

Keywords

  • Temporal Interference Stimulation (TIS)
  • Functional Magnetic Resonance Imaging (fMRI)
  • Non-invasive Brain Stimulation (NIBS)
  • Neuromodulation
04

Who can participate

Ages eligible
45 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with Parkinson's Disease according to the Movement Disorder Society (MDS) clinical diagnostic criteria.
  • Hoehn \& Yahr Stage I-III (mild to moderate severity).
  • Aged 45 to 65 years.
  • Right-handed. Stable medication regimen for at least 1 hour before Phase A fMRI sessions and agreement to maintain a stable dosage during the 2-week Phase B intervention (unless clinically necessary).
  • Able to provide by the participant or a legal guardian.

Exclusion criteria

Exclusion Criteria:

  • MRI , such as implanted DBS electrodes, cardiac pacemakers, or other metal implants.
  • Significant cognitive impairment ( score \< 24) or severe psychiatric symptoms.
  • History of epilepsy or structural brain lesions, including severe cerebral atrophy or cerebrovascular disease.
  • Severe head tremors that would interfere with MRI scanning quality.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    130 Hz TIS Group

    Participants receive active Temporal Interference Stimulation (TIS) with a 130 Hz envelope frequency targeting the right globus pallidus internus (GPi).

    Device: Temporal Interference Stimulation (130 Hz)

  • Experimental
    40 Hz TIS Group

    Participants receive active TIS with a 40 Hz envelope frequency targeting the right GPi.

    Device: Temporal Interference Stimulation (40 Hz)

  • Sham comparator
    Sham Group

    Participants receive sham stimulation targeting the right GPi.

    Device: Sham Temporal Interference Stimulation

Interventions

  • DeviceTemporal Interference Stimulation (130 Hz)

    High-frequency sinewave currents (carrier frequency: 2000 Hz and 2130 Hz) are delivered via two pairs of scalp electrodes. The current intensity is 2-4 mA (individualized). In Phase B, stimulation lasts 30 minutes daily for 2 weeks (10 sessions).

  • DeviceTemporal Interference Stimulation (40 Hz)

    High-frequency sinewave currents (carrier frequency: 2000 Hz and 2040 Hz) are delivered via two pairs of scalp electrodes. Parameters are identical to the 130 Hz group except for the envelope frequency.

  • DeviceSham Temporal Interference Stimulation

    The device provides only a 20-second ramp-up and 20-second ramp-down of current to mimic the skin sensation of active stimulation, without continuous therapeutic stimulation.

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS-III) total score.

    The MDS-UPDRS Part III is a clinician-rated scale used to assess the motor signs of Parkinson's disease. It includes 18 items (33 scores total), with each item ranging from 0 (normal) to 4 (severe). The total score ranges from 0 to 132, where higher scores represent greater motor impairment.

    Time frame: Baseline, 2 weeks (immediately after the 10th intervention session), and 1 month (follow-up).

Secondary outcomes

  1. Changes in Brain Network Functional Connectivity and Amplitude of Low-frequency Fluctuations (ALFF).

    Assessed using resting-state fMRI to quantify the acute and long-term regulatory effects of TIS on the basal ganglia-thalamus-cortical circuit.

    Time frame: Baseline, 20 minutes (during concurrent TIS), and 8 minutes (immediately post-stimulation) for Phase A ; Baseline and 2 weeks for Phase B.

07

Study locations

1 site
  • Nanjing Brain Hospital (Affiliated Brain Hospital of Nanjing Medical University)
    Nanjing, Jiangsu 210029, China
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared to protect the privacy of the patients and because the data is currently being used for institutional research and future academic publications.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Aug 2026, 5 months later.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 5 months is below that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2026
First posted
Mar 18, 2026
StartEst.
Mar 20, 2026
Primary completionEst.
Aug 31, 2026
CompletionEst.
Mar 31, 2027
Last update
Mar 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07480317
Lead sponsor
Jiangsu Province Nanjing Brain Hospital
Responsible party
Weiguo Liu (Professor, Chief Physician, Jiangsu Province Nanjing Brain Hospital) — Principal investigator
First posted
Mar 18, 2026
Start date
Mar 20, 2026 (estimated)
Primary completion
Aug 31, 2026 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Mar 24, 2026

Study contacts

Weiguo Liu, MD, PhD
Contact
wgliunbh@sina.com
86-13914725569

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion